Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) have created a new initiative to advance radiopharmaceuticals in Canada.
The CDPC-adMare Radiopharmaceutical Initiative (CARI) combines the resources of the two companies in order to commercialize promising radiopharmaceutical innovations.
CARI's goal is to discover radiopharmaceutical opportunities from academia and early-stage companies in order to establish related drug development programs. CDPC and adMare also hope to generate a proof of principle and other data to support commercialization efforts.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
